Pharmaceutical R&D
Search documents
Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation
TMX Newsfile· 2026-03-23 12:00
Core Insights - Telescope Innovations Corp. is enhancing its capabilities in automated chemistry sampling technologies and Self-Driving Laboratories by expanding the consulting role of Dr. Joel M. Hawkins, an expert in automating complex chemistry workflows [1][3] Company Overview - Telescope Innovations Corp. specializes in developing enabling technologies and services for the pharmaceutical and high-value chemical industries, focusing on reaction sampling technology, intelligent automation, and advanced chemical manufacturing [4] - The company offers products such as reaction sampling systems for real-time analysis, flexible robotic platforms, and AI software to improve experimental throughput, efficiency, and data quality [4] Key Developments - Dr. Hawkins has a history of applying automation and data-rich process analytics to enhance chemical development, with previous work at Pfizer and Technobis demonstrating the acceleration of chemical process optimization in pharma R&D [2] - His contributions have already advanced Telescope's lithium-sector process IP development, particularly in the ReCRFT™ and DualPure™ technologies [3] - The company is collaborating with AGI to develop next-generation chemical reactors, further expanding its automated sampling technology initiatives [6] Technology Focus - The DirectInject-LC™ platform is highlighted as Telescope's flagship automated reaction sampling technology [6] - Self-Driving Laboratories (SDLs) are being deployed to integrate robotics, inline analytics, and AI, enabling faster and more efficient chemistry research compared to traditional methods [6]
Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF
Prnewswire· 2026-02-09 12:14
Core Insights - XtalPi Inc. has successfully deployed an automated formulation stability testing workstation at BASF, enhancing BASF's R&D capabilities in the chemical industry [1][2][3] - This collaboration marks a significant milestone for XtalPi, showcasing its technological leadership and ability to provide scalable solutions for industry leaders [1][5] Company Overview - XtalPi is a global leader in AI- and robotics-driven R&D platforms, focusing on innovation in pharmaceuticals, petrochemicals, new energy, and advanced materials [1][9] - Founded in 2015 by MIT physicists, XtalPi integrates quantum physics, AI, and robotics to deliver digital and intelligent R&D solutions across various industries [9] Collaboration with BASF - BASF, a major player in the chemical industry, operates in diverse sectors and is committed to green transformation [2][10] - The automated workstation developed by XtalPi addresses BASF's challenges in traditional manual workflows, enhancing efficiency, accuracy, and standardization in testing processes [3][4] Technological Advancements - XtalPi's automated system integrates sample management, analytical testing, and data management into a cohesive workflow, significantly improving operational efficiency [1][3] - The modular and standardized platform allows for rapid deployment and customization, meeting the unique requirements of BASF [4][5] Market Position and Future Outlook - XtalPi's solutions are deployed across various industries, including pharmaceuticals and renewable energy, positioning the company for growth in trillion-dollar markets [7] - The company aims to deepen strategic partnerships with global industry leaders to drive advancements in AI and robotic experimentation [8]
InSilico Medicine Cayman TopCo(03696) - OC Announcement - Appointment
2025-11-10 16:00
INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 (Incorporated in the Cayman Islands with limited liability) WARNING The publication of this announcement is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. By viewing this announcement, you acknowledge, accept and agree with InSilico Medicine Cayman TopCo (英矽智能) (the "Company"), its joint spon ...